IO Biotech's Phase 3 Trial Of IO102-IO103 With KEYTRUDA In Advanced Melanoma To Continue Following IDMC Review; No New Safety Signals Observed, Primary Endpoint Of Progression-Free Survival Expected In First Half Of 2025
Author: Benzinga Newsdesk | August 30, 2024 04:07pm